IQVIA Holdings Inc. (NYSE:IQV) Receives $241.50 Consensus Target Price from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two research firms that are currently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $241.50.

Several equities research analysts have recently weighed in on IQV shares. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Barclays reaffirmed an "equal weight" rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Mizuho decreased their price target on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IQV. American National Bank & Trust bought a new position in shares of IQVIA during the 1st quarter worth $26,000. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at approximately $33,000. ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth $39,000. Finally, Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter worth about $44,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 0.6 %

Shares of NYSE:IQV traded up $0.90 during midday trading on Friday, hitting $150.05. 54,186 shares of the stock were exchanged, compared to its average volume of 1,386,175. The business's 50-day moving average price is $180.02 and its 200 day moving average price is $198.45. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The stock has a market capitalization of $26.46 billion, a price-to-earnings ratio of 19.99, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts predict that IQVIA will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.